NPM1突变成人急性髓系白血病的共突变模式与预后意义:HARMONY研究
该研究基于HARMONY联盟数据库,分析强化治疗的成人NPM1突变急性髓系白血病(AML)患者,开发了纳入FLT3-ITD、DNMT3A、IDH1/IDH2和TET2共突变组合的风险分类。在训练队列(n=1001)中,该分类将51.8%患者归为有利风险、24.8%为中危、23.4%为不良风险,中位总生存期(OS)分别为14.4、2.2和0.9年(p<0.001),并将42.7%患者重新分入不同的ELN 2022风险类别,结果在内部和外部验证队列中均得到证实。
要点
- HARMONY分类基于FLT3-ITD、DNMT3A、IDH1/IDH2和TET2共突变组合,将NPM1突变AML分为有利、中危和不良风险三组。
- 训练队列中三组中位OS分别为14.4、2.2和0.9年(p<0.001),42.7%患者被重新分类至不同ELN 2022风险类别。
- 首次完全缓解(CR1)时行异基因造血干细胞移植(allo-HSCT)在不良风险亚组中获益最大。
核心结论
- HARMONY分类为成人NPM1突变AML提供了细化的遗传风险分层,可能影响allo-HSCT决策。
研究设计与样本
- 基于HARMONY联盟数据库,分析强化治疗的成人NPM1突变AML患者,训练队列来自临床试验(n=1001),内部验证队列更接近真实世界(n=762),外部验证队列来自UK-NCRI试验(n=585)。
主要发现
- 训练队列中HARMONY分类将51.8%患者归为有利风险、24.8%为中危、23.4%为不良风险,中位OS分别为14.4、2.2和0.9年(p<0.001)。
- 该分类将42.7%的NPM1突变患者重新分入不同的ELN 2022风险类别。
- 结果在内部和外部验证队列中均得到证实。
- 首次完全缓解(CR1)时行allo-HSCT在NPM1突变不良风险亚组中显示最高获益。
关键数值与推荐
- HARMONY分类纳入FLT3-ITD、DNMT3A、IDH1/IDH2和TET2基因的共突变组合。
- 训练队列中有利、中危、不良风险组的中位OS分别为14.4、2.2和0.9年(p<0.001)。
临床怎么用
- 对成人NPM1突变AML患者可应用HARMONY分类进行细化风险分层,辅助allo-HSCT决策,尤其不良风险亚组在CR1时行allo-HSCT获益最大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
NPM1-mutated (NPM1-mut) acute myeloid leukemia (AML) is generally associated with a more favorable outcome, although the presence of additional gene mutations can influence patient prognosis. We analyzed intensively-treated adult NPM1-mut AML patients included in the HARMONY Alliance database. A newly developed risk classification, which included combinations of co-mutations in FLT3-ITD, DNMT3A, IDH1/IDH2, and TET2 genes, was applied to a training cohort of NPM1-mut AML patients included in clinical trials (n = 1001), an internal validation cohort more representative of real-world settings (n = 762), and an external validation cohort enrolled in UK-NCRI trials (n = 585). The HARMONY classification considered 51.8% of the NPM1-mut AML training cohort patients as favorable, 24.8% as intermediate, and 23.4% as adverse risk, with median overall survival (OS) of 14.4, 2.2, and 0.9 years, respectively; p < 0.001), thereby reclassifying 42.7% of NPM1-mut patients into a different European LeukemiaNet (ELN) 2022 risk category. These results were confirmed both in an internal and external validation cohort. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in first complete remission (CR1) showed the highest benefit in the NPM1-mut adverse-risk subgroup. The HARMONY classification provides the basis for a refined genetic risk stratification for adult NPM1-mut AML with potential clinical impact on allo-HSCT decision-making.
引用
- Hernández-Sánchez A, Villaverde Ramiro Á, Sträng E, et al. Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia - a HARMONY study. Leukemia. 2026. PMID: 41535568. doi:10.1038/s41375-025-02851-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。